[Relationship between methicillin resistant Staphylococcus aureus from inpatients and parenteral antibiotics]. 2003

Reiko Ota, and Choichirou Takahashi, and Tadashi Shiraishi, and Makoto Tominaga
Department of Clinical Laboratory, Yamagata University Hospital.

We examined the relationship between clinical isolates from inpatients, mainly methicillin resistance Staphylococcus aureus (MRSA), and usage of parenteral antibiotics in Yamagata University Hospital and comparison of the relationship of the previous decade and the present. The first period was from 1988 to 1990 in a row, and the second period was from 1998 to 2000 in a row. In the first period, third generation cephems were used much and usage of antibiotics was shifted from latamoxef to flomoxef. Isolations of MRSA were decreased. In the second period, the third generation cephems decreased, cefazolin and the forth generation cephems increased. And also decrease in usage of penicillins was observed. Isolations of MRSA were increased. For further examination of these relation, we studied by statistical analysis the number of MRSA patients and usage of antibiotics per month in the second period. MRSA patients showed positive correlation with cephems and carbapenems, negative correlation with penicillins. In major antibiotics MRSA patients showed positive correlation with cefazolin, negative correlation with piperacillin. In multiple linear regression analysis, MRSA patients calculated multiple regression model including cefazolin. In conclusion, it was suggested that cefazolin related with MRSA. It has been estimated that cefazolin were administered before the appearance of MRSA. It is a possibility that cefazolin related with the appearance or fixation of MRSA.

UI MeSH Term Description Entries
D007297 Inpatients Persons admitted to health facilities which provide board and room, for the purpose of observation, care, diagnosis or treatment. Inpatient
D002437 Cefazolin A semisynthetic cephalosporin analog with broad-spectrum antibiotic action due to inhibition of bacterial cell wall synthesis. It attains high serum levels and is excreted quickly via the urine. Cephazolin,Ancef,Cefamedin,Cefamezine,Cefazolin Sodium,Cephamezine,Cephazolin Sodium,Gramaxin,Kefzol,Sodium Cephazolin,Totacef,Cephazolin, Sodium,Sodium, Cefazolin,Sodium, Cephazolin
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D013203 Staphylococcal Infections Infections with bacteria of the genus STAPHYLOCOCCUS. Infections, Staphylococcal,Staphylococcus aureus Infection,Staphylococcal Infection,Staphylococcus aureus Infections
D013211 Staphylococcus aureus Potentially pathogenic bacteria found in nasal membranes, skin, hair follicles, and perineum of warm-blooded animals. They may cause a wide range of infections and intoxications.
D016106 Methicillin Resistance Non-susceptibility of a microbe to the action of METHICILLIN, a semi-synthetic penicillin derivative. Methicillin-Resistant,Methicillin Resistant,Resistance, Methicillin

Related Publications

Reiko Ota, and Choichirou Takahashi, and Tadashi Shiraishi, and Makoto Tominaga
November 1985, Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases,
Reiko Ota, and Choichirou Takahashi, and Tadashi Shiraishi, and Makoto Tominaga
October 2003, The Journal of hospital infection,
Reiko Ota, and Choichirou Takahashi, and Tadashi Shiraishi, and Makoto Tominaga
January 2016, Journal of intercultural ethnopharmacology,
Reiko Ota, and Choichirou Takahashi, and Tadashi Shiraishi, and Makoto Tominaga
May 2018, Royal Society open science,
Reiko Ota, and Choichirou Takahashi, and Tadashi Shiraishi, and Makoto Tominaga
November 2011, Biotechnology journal,
Reiko Ota, and Choichirou Takahashi, and Tadashi Shiraishi, and Makoto Tominaga
April 2021, Antibiotics (Basel, Switzerland),
Reiko Ota, and Choichirou Takahashi, and Tadashi Shiraishi, and Makoto Tominaga
January 2007, American journal of rhinology,
Reiko Ota, and Choichirou Takahashi, and Tadashi Shiraishi, and Makoto Tominaga
May 1991, The Journal of infectious diseases,
Reiko Ota, and Choichirou Takahashi, and Tadashi Shiraishi, and Makoto Tominaga
February 2008, The Journal of antimicrobial chemotherapy,
Reiko Ota, and Choichirou Takahashi, and Tadashi Shiraishi, and Makoto Tominaga
January 1992, The Journal of hospital infection,
Copied contents to your clipboard!